Repoxegen Therapeutics, Inc
Publicly observedLos Altos Hills, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Los Altos Hills | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Repoxegen Therapeutics, Inc | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | VMBPKKEESTN1 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant22 Sept 2026Publicly observed
NIH SBIR/STTR award: Targeting fatty acid metabolic disequilibrium-mediated neuroinflammation asa novel treatment for Alzheimer's disease
USD 1,199,745.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.